Markets:

Overview

News

Currencies

International

Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.930 +0.090 (+3.17%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

What 5 Analyst Ratings Have To Say About Rocket Pharmaceuticals ↗

August 11, 2023

Via Benzinga

Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

August 10, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

3 Small-Cap Stocks You Can’t Ignore Now ↗

June 12, 2023

Finding promising small-cap stocks can be like a winning lottery ticket, providing years of steady and increasing gains to investors.

Via InvestorPlace

Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) Sets New 52-Week High in Friday Session

June 09, 2023

Via Investor Brand Network

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

June 08, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings for Rocket Pharmaceuticals ↗

May 23, 2023

Via Benzinga

Analyst Ratings for Rocket Pharmaceuticals ↗

May 05, 2023

Via Benzinga

Rocket Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

May 31, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)

May 23, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 19, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

5 Analysts Have This to Say About Rocket Pharmaceuticals ↗

April 19, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Rocket Pharmaceuticals ↗

February 28, 2023

Via Benzinga

Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

May 09, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress

May 04, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference

May 03, 2023

From Rocket Pharmaceuticals, Inc

Via Business Wire

The Latest Analyst Ratings for Rocket Pharmaceuticals ↗

January 23, 2023

Via Benzinga

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

April 11, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative' ↗

April 07, 2023

Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.

Via Benzinga

Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage

April 04, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference

March 01, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention ↗

February 28, 2023

Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia,...

Via Benzinga

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

February 27, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

February 09, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

February 07, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

January 13, 2023

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

Via MarketBeat

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

January 09, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗

December 23, 2022

Gainers

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

All News about Rocket Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today